What happened with TNDM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Tandem Diabetes Care helps people with insulin-dependent diabetes manage insulin delivery through its t:slim X2 and Mobi pumps. Most customers connect their pumps to continuous glucose monitors, whose readings feed software such as Control-IQ+ to automate insulin delivery. Pumps last for years, while insulin cartridges and infusion sets need replacing every few days. Nearly all revenue comes from these pumps and supplies, so retaining users supports repeat supply purchases and eventual pump replacements.
Most sales go through independent distributors, and two distributors each account for a substantial share. Insurers and other healthcare payors cover much of patients’ purchase costs, making reimbursement central to sales. In the United States, coverage has generally paid for the pump upfront and supplies separately. Tandem is moving pharmacy-channel contracts toward a pay-as-you-go model that pays for ongoing supplies rather than the durable pump.
The business also depends on agreements with Dexcom and Abbott for compatible glucose monitors. Unomedical A/S, part of ConvaTec Group, supplies all currently marketed infusion sets. Tandem generally needs FDA clearance or approval before selling new regulated products or significantly modified devices in the United States; changes to approved components or manufacturing arrangements can also require regulatory review, limiting how quickly it can switch suppliers.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Tandem Diabetes Care’s recurring supply sales depend on reliable deliveries from Unomedical, the ConvaTec Group subsidiary supplying all its currently marketed infusion sets.
Insulet’s tubeless Omnipod systems compete with Tandem’s insulin pumps for insulin-dependent patients and the clinicians who prescribe their treatment. Watch Omnipod sales and clinician acceptance for signs of pressure on Tandem’s pump business.
MiniMed Group competes worldwide with Tandem for people requiring intensive insulin therapy, selling pumps, software that determines insulin doses and regularly replaced supplies as an integrated system. Its sales outside the United States—about 70% of revenue in fiscal 2026—are particularly relevant to Tandem’s international competition.
Beta Bionics competes with Tandem for U.S. patients with type 1 diabetes, selling the iLet insulin pump and its replacement cartridges and infusion sets, with orders typically billed to insurers directly or through distributors. Watch iLet uptake: the pump cannot use third-party cartridges or infusion sets, so its users also buy its recurring supplies.
Tandem’s automated insulin-delivery sales depend partly on the availability and adoption of Dexcom’s G6 and G7 monitors, which measure patients’ glucose and feed readings into Tandem’s pumps. Watch G6 and G7 supply, pricing and continued pump-integration agreements rather than Dexcom’s overall sales alone.
Medtronic’s Diabetes Business competes with Tandem to sell insulin pumps and replacement supplies to diabetes patients served by the same prescribers, although Medtronic has much broader healthcare exposure. Its diabetes pump and consumable sales are more relevant to Tandem than company-wide results.
Tandem’s automated insulin-delivery offering depends partly on Abbott’s supply and development of FreeStyle Libre sensors, which measure patients’ glucose for use by compatible Tandem pumps. Watch FreeStyle Libre 3 Plus integration: Tandem launched it for t:slim X2 in the United States in December 2025 and planned to add it to Mobi.
DexCom, Inc. earningsDXCM
Dexcom’s report will help show whether G6 and G7 sensor supply, pricing and integration arrangements continue to support Tandem’s automated insulin-delivery pumps.
Watch Dexcom’s comments on G6 and G7 supply and pricing, alongside any update on integration with Tandem pumps. Reliable supply and workable terms would support a dependable compatible sensor input for Tandem; shortages, pricing pressure or changes to integration arrangements could limit its options or add cost and development work.
Insulet Corporation earningsPODD
Insulet’s report will show whether its tubeless Omnipod systems are winning more business among the patients and prescribers it shares with Tandem.
Compare Omnipod sales growth with the trend in Tandem’s pump sales. Faster growth at Insulet would show that more patients and prescribers in the shared market may be choosing Omnipod, increasing pressure on Tandem to win pump customers. Slower growth would mean less evidence of that pull, not proof that Tandem gained those customers.
Tandem Diabetes Care, Inc. earningsThis company
Tandem’s report will show whether growing supply sales through the pharmacy channel are beginning to offset the effect of its changing pump-sales model on revenue and gross margin.
Read pump sales, supplies sales and gross margin together. Stronger supplies with a steady margin would show recurring purchases are beginning to make up for the lower upfront revenue and margin that can come with the pharmacy model. If supplies lag or margin falls, the offset is not yet sufficient. The question is whether Tandem can make recurring supply sales carry the shift in how it gets paid for pumps.
